Godalming, UK-based Sinclair Pharma says that it has signed its first marketing distribution agreement for its products in India with one of the country’s leading drugmakers Wockhardt.

The 10-year deal initially covers four products – Sinclair’s flagship eczema drug Atopiclair, the gum disease treatment Decapinol, Aloclair for mouth ulcers and the acne drug Papulex. The firm will provide finished product to Wockhardt but then switch to local manufacture as soon as possible, thus enhancing its margins.

Chief executive Michael Flynn described Wockhardt as “a dynamic and rapidly growing company and we hope this is the first step towards forging a long-term and mutually rewarding relationship”. He added that Sinclair has a very active programme pursuing opportunities in the BRIC (Brazil, Russia, India, China) countries and the Middle East “which we believe offer substantial growth opportunities for the sales of our products in the coming years”.

Dr Flynn concluded by saying that “we approach the end of our most successful year witnessing a rewarding level of growth and a new era” as Sinclair starts to reap the benefit of “several years’ investment in developing new products and establishing effective, geographically diverse distribution”.

His firm’s new partner has more than 7,500 employees and turnover last year reached $670 million, while Wockhardt’s sales grew 50% in the first quarter. The Indian pharmaceutical market is currently valued at $7 billion, with a growth rate of 17% compared to 7% for the global industry.